Cargando…

Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib

Granulocytic myeloid-derived suppressor cells (Gr-MDSCs) promote immune evasion and resistance to immunotherapeutics in a variety of malignancies. Our previous study showed that dual PI3K/mTOR inhibitor Dactolisib impaired the viability and immunosuppressive function of Gr-MDSCs, and significantly s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Guoqiang, Jin, Zhijian, Lu, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178187/ https://www.ncbi.nlm.nih.gov/pubmed/32230980 http://dx.doi.org/10.3390/ijms21072337

Ejemplares similares

Unraveling the therapeutic potential of GANT61/Dactolisib combination as a novel prostate cancer modality
por: Youssef, Mohamed, et al.
Publicado: (2022)

Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer
por: Wen, Jiling, et al.
Publicado: (2020)

Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models
por: Netland, I. A., et al.
Publicado: (2016)

Immunotherapy of targeting MDSCs in tumor microenvironment
por: Sui, Hongshu, et al.
Publicado: (2022)

Improving cancer immunotherapy by targeting the STATe of MDSCs
por: de Haas, Nienke, et al.
Publicado: (2016)

The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
por: Shi, Fei, et al.
Publicado: (2017)

NVP-BEZ235 (Dactolisib) Has Protective Effects in a Transgenic Mouse Model of Alzheimer’s Disease
por: Bellozi, Paula Maria Quaglio, et al.
Publicado: (2019)

Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment
por: Gao, Xidan, et al.
Publicado: (2021)

Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
por: Shi, Fei, et al.
Publicado: (2018)

Myeloid-Derived Suppressor Cells (MDSCs) in Haematology
por: Bizymi, Nikoleta, et al.
Publicado: (2021)

Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies
por: Shou, Dawei, et al.
Publicado: (2016)

Targeting MDSCs enhance therapeutic vaccination responses against lung cancer
por: Srivastava, Minu K., et al.
Publicado: (2012)

MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target
por: Liu, Haoyu, et al.
Publicado: (2023)

Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
por: Araujo, John C, et al.
Publicado: (2013)

Neuroprotective effects of the anticancer drug NVP-BEZ235 (dactolisib) on amyloid-β 1–42 induced neurotoxicity and memory impairment
por: Bellozi, Paula Maria Quaglio, et al.
Publicado: (2016)

Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer
por: Li, Jianneng, et al.
Publicado: (2017)

GR Dimerization and the Impact of GR Dimerization on GR Protein Stability and Half-Life
por: Louw, Ann
Publicado: (2019)

New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs
por: Lakshmanachetty, Senthilnath, et al.
Publicado: (2021)

Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer—Looking Back and Forward
por: Okła, Karolina
Publicado: (2023)

Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells
por: Tian, Jun, et al.
Publicado: (2018)

Mesenchymal stem cells inhibited the differentiation of MDSCs via COX2/PGE2 in experimental sialadenitis
por: Qi, Jingjing, et al.
Publicado: (2020)

New roles of Rb1 in expansion of MDSCs in cancer
por: Youn, Je-In, et al.
Publicado: (2013)

LncRNA Snhg6 regulates the differentiation of MDSCs by regulating the ubiquitination of EZH2
por: Lu, Wei, et al.
Publicado: (2021)

Multifunctional Nanodrug Mediates Synergistic Photodynamic Therapy and MDSCs‐Targeting Immunotherapy of Colon Cancer
por: Ding, Dongbing, et al.
Publicado: (2021)

Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib
por: Montenegro, Raquel Carvalho, et al.
Publicado: (2020)

The Effect of Immunosuppressive Drugs on MDSCs in Transplantation
por: Yang, Fan, et al.
Publicado: (2018)

CXCR2(+) MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion
por: Zhu, Ha, et al.
Publicado: (2017)

Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy
por: He, Wei, et al.
Publicado: (2016)

High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model
por: Kiyuna, Tasuku, et al.
Publicado: (2016)

Mesenchymal Stem Cell Enhances the Function of MDSCs in Experimental Sjögren Syndrome
por: Tian, Jie, et al.
Publicado: (2020)

Evolution of Our Understanding of Myeloid Regulatory Cells: From MDSCs to Mregs
por: Manjili, Masoud H., et al.
Publicado: (2014)

Dasatinib targets c-Src kinase in cardiotoxicity
por: Elmadani, Manar, et al.
Publicado: (2023)

MDSCs are involved in the protumorigenic potentials of GM-CSF in colitis-associated cancer
por: Ma, Ning, et al.
Publicado: (2017)

Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib
por: Chien, Wenwen, et al.
Publicado: (2018)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs
por: Francian, Alexandra, et al.
Publicado: (2017)

Interplay between myeloid-derived suppressor cells (MDSCs) and Th17 cells: foe or friend?
por: Wen, Liang, et al.
Publicado: (2016)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Immune suppression by myeloid-derived suppressor cells, MDSCs, in MYCN-driven neuroblastoma provides a potential target for cancer immunotherapy
por: Eissler, Nina, et al.
Publicado: (2014)

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis
por: Koreckij, T, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_dhv0a2c1uinqterllbr2rfqnu8